
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
However, the future of TKI combinations for these rare tumours is uncertain
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
Several studies report on promising data with immunomodulation and alternative approaches
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.